BioSpace News Archive

Merakris Therapeutics, LLC, a biotechnology company that is developing advanced biologic technologies derived from perinatal cells and tissues, files a Pre-IND meeting request with the FDA for Dermacyte Liquid (Amniotic Wound Care Liquid) for subcutaneous injection for the treatment of non-healing venous stasis ulcers.

AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first quarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2019.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, February 13, 2020 at 8:00 a.m. ET to report its fourth quarter and full year 2019 financial results and other business highlights.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal second-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Thursday, February 6, 2020.

Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy, announced today that the Company has achieved the milestone of 100,000 knee joint replacement implants manufactured and sold in the U.S.

Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, and ImagineMIC™ announced a partnership agreement today to drive improved outcomes and lower healthcare costs for patients with chronic conditions.

Medivir AB reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims.

2019 delivered the strongest financial results for Orexo, with the fourth quarter being no exception.